Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

W. Kantoff, Philip; S. Higano, Celestia; D. Shore, Neal; Roy Berger, E.; J. Small, Eric; F. Penson, David; H. Redfern, Charles; C. Ferrari, Anna; Dreicer, Robert; B. Sims, Robert; Xu, Yi; W. Frohlich, Mark; F. Schellhammer, Paul

doi:10.1056/nejmoa1001294

Public

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Published in New England Journal of Medicine • Jul 28, 2010

Authors:

Philip W. Kantoff

Celestia S. Higano

Neal D. Shore

Abstract

BACKGROUND: Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. METHODS: In this double-blind, placebo-controlled, multicenter phase 3 trial, we randomly assigned 512 p...

Subject

Medicine

Prostate cancer

Immunotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!